Cosmos Health Inc. (NASDAQ: COSM) reported record financial results for the second quarter and first half of 2026, marking a significant milestone with an adjusted annualized revenue run-rate exceeding $75 million. The Chicago-based healthcare group recorded quarterly revenue of $18.99 million, a 28.8% increase from $14.75 million in the same period last year, and first-half revenue of $36.91 million, up 29.7% from $28.46 million in the prior-year period.

While the company continued to report a GAAP net loss, operational metrics showed marked improvement. Adjusted gross profit reached $1.84 million in Q2 2026, up 58.4% year-over-year, with adjusted gross margin expanding 165 basis points to 9.54%. Adjusted EBITDA improved to a loss of $1.13 million from a loss of $1.31 million in Q2 2025, reflecting operating leverage as expenses grew at roughly half the rate of revenue.

Financial Performance

The company’s top-line growth was driven by higher sales volumes across all core segments, including Decahedron’s near-doubling of revenue in the United Kingdom and Cana Laboratories building its contract manufacturing orderbook to over 25 million units. However, the GAAP net loss widened to $6.09 million in Q2 2026 from $2.83 million in Q2 2025, primarily due to $2.65 million in non-cash charges related to fair value adjustments on financing arrangements.

For the first half, total operating expenses were $8.00 million, up 19.6%, which remained well below the 29.7% revenue growth rate. Salaries and wages declined 0.7% year-over-year in Q2 despite significant revenue expansion, demonstrating positive operating leverage.

Balance Sheet and Capital Structure

Cosmos Health strengthened its capital structure during the first half of 2026. Total liabilities decreased by $6.27 million, or 13.3%, to $40.79 million as of June 30, 2026, from $47.05 million at year-end 2025. Conversely, total stockholders' equity increased by $2.25 million, or 12.2%, to $20.67 million. The liabilities-to-assets ratio improved by 550 basis points to 66.4%.

Liquid assets totaled $4.15 million, comprising cash and cash equivalents of $2.45 million and digital assets and marketable securities of $1.70 million. The company also initiated a share repurchase program of up to $5.0 million on June 26, 2026, having repurchased 5,112,000 shares for approximately $1.11 million as of the reporting date.

What the Numbers Show

The divergence between the widening GAAP net loss and the improving adjusted EBITDA highlights that the primary driver of the bottom-line deterioration is non-operational. Specifically, the $2.65 million in non-cash fair value adjustments on financing arrangements accounts for a substantial portion of the $6.09 million net loss. Excluding these items, the core business is demonstrating improved profitability, evidenced by the 58.4% surge in adjusted gross profit and the reduction in adjusted EBITDA losses, suggesting that operational efficiencies are beginning to translate into better unit economics despite the accounting noise from financing structures.

Cosmos Health Inc. (NASDAQ: COSM) announced on July 27, 2026, the active development of a flexible, technology-driven subscription platform for its consumer health products, marking a significant step in its broader technology transformation. The platform is designed to generate predictable, recurring revenue by serving both business-to-consumer (B2C) and business-to-business (B2B) channels with personalized health packages. This move addresses the company’s strategic goal of building a scalable, technology-enabled revenue stream that creates long-term value for shareholders.

The platform offers customers three entry paths: a free consultation with a nutritionist, engagement with an AI-powered assistant, or the ability to build their own package. Based on individual health and wellness goals, the system assembles personalized packages consisting primarily of Cosmos Health’s proprietary products, supplemented by third-party items where necessary. Future enhancements are expected to include deeper AI-driven personalization and the potential integration of at-home testing and diagnostic kits to inform subscriptions with individualized health insights.

Platform Features and Business Models

The subscription service supports multiple purchasing models tailored to different customer segments. Key features include:

Greg Siokas, CEO of Cosmos Health, stated, "We are building a subscription platform designed to meet customers wherever they are—whether they are individual consumers, corporate clients, or one-time buyers—and turn each interaction into a lasting relationship. By combining personalized guidance with technology, and over time AI-driven personalization and diagnostic insights, we intend to deliver a differentiated consumer health experience while building the predictable, recurring revenue that creates long-term value for our shareholders."

What the Numbers Show

The strategic shift toward a subscription model is underpinned by early operational data from the U.S. market. The platform builds on the subscription model launched for NOOR Collagen, which has delivered a repeat purchase rate above 60%. This metric indicates strong product-market fit and customer retention potential, providing a foundational proof point for scaling the broader platform across Cosmos Health’s portfolio of proprietary brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub.

Cosmos Health intends to expand the platform into international markets as part of its strategy to diversify revenue streams beyond traditional pharmaceutical distribution. The company, incorporated in Nevada in 2009, operates vertically integrated manufacturing facilities in the European Union through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA). The integration of digital subscription services complements its existing physical distribution network across Europe, Asia, and North America.